Current Heart Failure Reports

, Volume 10, Issue 1, pp 101–107

Ventricular Assist Devices: Is Destination Therapy a Viable Alternative in the Non-Transplant Candidate?

Authors

  • Tara Hrobowski
    • Henry Ford Heart and Vascular Institute, Henry Ford Hospital
    • Henry Ford Heart and Vascular Institute, Henry Ford Hospital
    • Advanced Heart Failure and Cardiac Transplantation, Center for Health Services ResearchWayne State University, Henry Ford Hospital
Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise (AK Hasan, Section Editor)

DOI: 10.1007/s11897-012-0123-7

Cite this article as:
Hrobowski, T. & Lanfear, D.E. Curr Heart Fail Rep (2013) 10: 101. doi:10.1007/s11897-012-0123-7

Abstract

The topic of this article, stated a more familiar way, is whether left ventricular assist devices (LVADs) are ready for ‘Primetime’ as a therapeutic option in and of themselves. In order to provide an update and insight on this question, we briefly review from where the field has come, and in more detail describe its current state and where we are heading. We believe the short answer to this question is ‘Yes’, but like many things, a short answer is not adequate. Here we attempt to deliver a more comprehensive answer, providing some historical context, outlining the great achievements that have been made, as well as the many challenges that still remain before LVADs become a truly mainstream therapy.

Keywords

Left ventricular assist deviceMechanical circulatory supportRotary pumpsEndstage heart failure

Copyright information

© Springer Science+Business Media New York 2012